Ebv-positive Diffuse Large B-cell Lymphoma Not Otherwise Specified

• CLINICAL_TRIALS research · 2026-04-23
  Clinical Trial Update: Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma [Phase 2]

  A Phase 2 clinical trial update evaluating epcoritamab in combination with dose-adjusted EPOCH-R for aggressive B-cell non-Hodgkin lymphoma;…

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas [Phase 2, Phase 3]

  A Phase 2/Phase 3 trial is evaluating adding venetoclax to standard chemotherapy for high-grade B-cell lymphomas, including diffuse large B-…

• CLINICAL_TRIALS research · 2026-03-03
  Clinical Trial Update: Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma [Phase 1]

  Phase 1 trial evaluating polatuzumab vedotin with chemotherapy, with or without glofitamab, for untreated aggressive large B-cell lymphoma. …

• CLINICAL_TRIALS trial_result · 2024-10-16
  Clinical Trial Update: Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas [Phase 2]

  Phase 2 trial evaluating nivolumab with or without varlilumab in relapsed or refractory aggressive B-cell lymphomas, including multiple DLBC…

• CLINICAL_TRIALS research · 2024-10-16
  Clinical Trial Update: Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma [Phase 2]

  Phase 2 trial update on zanubrutinib combined with CAR T-cell therapy for recurrent or refractory aggressive B-cell non-Hodgkin lymphomas an…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2019-11-29
  Clinical Trial Update: Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS [Phase 2]

  Phase 2 trial evaluating Sintilimab plus R-CHOP in treatment-naive EBV-positive DLBCL, NOS.